

## [Dexamethasone](#)

Essential medicine status

Section:

### [3. Antiallergics and medicines used in anaphylaxis](#)

ATC codes: [H02AB02](#)

EMLc

Indication

Allergic or hypersensitivity conditions of unspecified type ICD11 code: [4A8Z](#)

INN

Dexamethasone

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Liquid:** 0.5 mg per 5 mL (as sodium phosphate) (EMLc) ; 2 mg per 5 mL (as sodium phosphate)

**Parenteral > General injections > unspecified:** 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

**Oral > Solid > tablet:** 0.5 mg (as dexamethasone base) ; 0.75 mg (as dexamethasone base) ; 1.5 mg (as dexamethasone base) ; 2 mg (as dexamethasone base) ; 4 mg (as dexamethasone base)

EML status history

First added in 1984 ([TRS 722](#))

Changed in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Dexamethasone](#)

DrugBank

[Dexamethasone](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of dexamethasone oral liquid 0.5 mg/5 mL (as sodium phosphate) to the EMLc; - the addition of dexamethasone tablets 0.5 mg, 0.75 mg, 1.5 mg and 4 mg (as dexamethasone base) to the EML and EMLc; - to modify the listings to reflect the amount of dexamethasone in terms of dexamethasone salt or dexamethasone base.